Complicated legacies: The human genome at 20
By Kahryn Maxson Jones, et al.,
Science
| 02. 05. 2021
Millions of people today have access to their personal genomic information. Direct-to-consumer services and integration with other “big data” increasingly commoditize what was rightly celebrated as a singular achievement in February 2001 when the first draft human genomes were published. But such remarkable technical and scientific progress has not been without its share of missteps and growing pains. Science invited the experts below to help explore how we got here and where we should (or ought not) be going. —Brad Wible
An ethos of rapid data sharing, more relevant than ever
By Kathryn Maxson Jones and Robert Cook-Deegan
Sharing data can save lives. The “Bermuda Principles” for public data disclosure are a fundamental legacy of producing the first human reference DNA sequence during the Human Genome Project (HGP) (1). Since the 1990s, these principles have become a touchstone for open science.
In February 1996, the leaders of the HGP gathered in Bermuda to discuss how to scale up production for a human reference DNA sequence. With some caveats, the consortium agreed that all sequencing centers would release their...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...